Mutants of vaccinia virus as oncolytic agents

• US 20070036758A1
• Filed: 07/08/2004
• Published: 02/15/2007
• Est. Priority Date: 07/08/2003
• Status: Abandoned Application

• Current Assignee: Bertram Jacobs, Chandra Mitnik, Jeffrey Langland
• Original Assignee: Bertram Jacobs, Chandra Mitnik, Jeffrey Langland
• Inventors: Jacobs, Bertram, Mitnik, Chandra, Langland, Jeffrey
• Application Number:
  US10/563,728
• Publication Number:
  US 20070036758A1
• Time in Patent Office: Days
• US Class Current: 424/93.200
• CPC Class Codes: A61K 35/768 Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/24162 by genetic engineering

Abstract

The present invention relates to mutant oncolytic vaccinia viruses and their use for selective destruction of cancer cells. The mutant vaccinia viruses of the invention include those having a reduced ability to inhibit the antiviral dsR-NA dependent protein kinase (PKR) and increased sensitivity to interferon. Such mutants include, for example, vaccinia viruses having mutations in the E3L and/or K3L regions. The invention is based on the discovery that vaccinia viruses having mutations in the E3L region are capable of replication in oncogenic cells resulting in cell lysis. The invention further provides methods for treating proliferative disorders, such as neoplasms, in a host comprising administration of mutant vaccinia virus under conditions which result in substantial lysis of the proliferating cancer cells.

Claims

1. A method of inducing lysis of proliferating cancer cells comprising contacting said cells with a vaccinia virus having an inactivating mutation in an interferon resistance gene.

2. The method of claim 1, wherein the cancer cells are ras-transformed cells.

3. The method of claim 1, wherein the cancer cells are breast cancer cells or prostate cancer cells.

4. The method of claim 1, wherein the inactivating mutation is in a gene selected from the group consisting of E3L, K3L, or a combination thereof.

5. The method of claim 4, wherein the inactivating mutation is selected from the group consisting of a deletion mutation, a substitution mutation, and a missense mutation.

6. The method of claim 4, wherein the inactivating mutation is in the E3L gene.

7. The method of claim 6, wherein the mutation is a deletion of the whole E3L gene.

8. The method of claim 1, wherein the mutant vaccinia virus has a reduced ability to inhibit PKR and increased sensitivity to interferon.

9. The method of claim 1, wherein said contacting comprises administering a therapeutic amount of the vaccinia virus to a mammal comprising proliferating cancer cells under conditions that permit contact between the vaccinia virus and the proliferating cancer cells.

10. The method of claim 9, wherein the administering is selected from the group consisting of intratumoral injection, intravenous injection, and intravascular injection.

11. A therapeutic composition for use in targeted cell lysis of a proliferating cancer cell comprising a vaccinia virus having an inactivating mutation in an interferon resistance gene and a carrier.

12. The therapeutic composition of claim 11, wherein the target cell is a breast cancer cell or prostate cancer cell.

13. The composition of claim 12, wherein the inactivating mutation is in a gene selected from the group consisting of E3L, K3L, or a combination thereof.

14. The composition of claim 13, wherein the inactivating mutation is selected from the group consisting of a deletion mutation, a substitution mutation, and a missense mutation.

15. The composition of claim 13, wherein the inactivating mutation is in the E3L gene.

16. The composition of claim 15, wherein the mutation is a deletion of the whole E3L gene.